Atomi Financial Group Inc. Purchases New Shares in argenx SE (NASDAQ:ARGX)

Atomi Financial Group Inc. bought a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 551 shares of the company's stock, valued at approximately $339,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. FMR LLC grew its position in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company's stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares during the period. Lord Abbett & CO. LLC bought a new position in argenx during the third quarter valued at $88,339,000. Perpetual Ltd bought a new stake in shares of argenx in the third quarter valued at $76,314,000. Wellington Management Group LLP lifted its position in shares of argenx by 13.0% during the 3rd quarter. Wellington Management Group LLP now owns 482,346 shares of the company's stock valued at $261,470,000 after buying an additional 55,617 shares during the last quarter. Finally, Alkeon Capital Management LLC increased its holdings in argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company's stock worth $187,018,000 after acquiring an additional 45,000 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

ARGX stock traded down $3.25 during trading on Friday, hitting $648.94. 217,137 shares of the company traded hands, compared to its average volume of 227,999. The company has a 50-day moving average of $625.94 and a 200-day moving average of $564.38. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21. The firm has a market capitalization of $39.18 billion, a PE ratio of -737.43 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. The firm had revenue of $588.88 million for the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same quarter last year, the business earned ($1.25) earnings per share. Sell-side analysts expect that argenx SE will post 2.78 EPS for the current year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of research reports. Wedbush reiterated an "outperform" rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a report on Friday, November 1st. Citigroup lifted their price target on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. Truist Financial reissued a "buy" rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. upped their price target on argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.